ABEO is a biopharmaceutical company focused on cell and gene therapies for serious, high-unmet-need conditions. Its lead product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell sheet-based gene therapy approved by the U.S. FDA for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe blistering disorder. I follow ABEO closely because of the therapy's first-to-market position, its durable one-time treatment model, and the company's efforts to broaden its pipeline into solid-tumor oncology and other indications. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, ABEO has declined approximately 46%, falling from a closing price of about $4.51 on October 21 to around $2.45. Most of that move occurred in a single session: on November 9, shares plunged roughly 39% on unusually heavy volume after the company reported third-quarter results and announced a stock-financed acquisition. The quarterly picture is similarly weak. From roughly $5.50 in mid-September, the stock has given back more than half its value, reflecting a sustained repricing as investors reassess the pace of ZEVASKYN's commercial ramp and the company's path to profitability.
The sharp November selloff was triggered by Abeona's Q3 2026 earnings release and a concurrent strategic announcement. The company reported net ZEVASKYN revenue of $13.5 million, up 18% sequentially, but slightly below the consensus estimate of $13.85 million. Adjusted loss per share of $0.08 beat expectations for a $0.18 loss. The more significant catalyst was dilution. Abeona announced the acquisition of Phase 3-ready APT-1011, now ABO-801, an oral therapy candidate for eosinophilic esophagitis, for $20 million in common stock, alongside a $30 million private placement. Investors reacted negatively to the equity-funded structure and the added development and execution risk. Manufacturing variability also drew scrutiny, as one batch in the quarter failed to qualify for revenue recognition due to out-of-specification results, and the company disclosed a planned biopsy-collection pause from mid-November through mid-January for an annual manufacturing shutdown.
The multi-month decline reflects a broader reassessment of Abeona's commercial trajectory. While ZEVASKYN achieved early payer coverage and expanded its Qualified Treatment Center network to eight sites, with 15 treatments completed since launch, the pace of revenue growth has lagged some investor expectations. The cash-burning profile, a quarterly cash burn of about $11.9 million, and uncertainty around manufacturing scalability and near-term throughput have pressured sentiment. The ABO-801 acquisition added pipeline optionality but also introduced new dilution and execution considerations that weighed on the stock throughout the quarter. From what I see, these elements combined to create sustained pressure on the shares.
Going forward, investors are likely to focus on ZEVASKYN revenue momentum and the pace of new patient treatments, particularly after the resumption of biopsy collection following the annual shutdown. Manufacturing utilization and gross-margin improvement remain key execution milestones, as does progress toward the planned capacity expansion. The ABO-801 development timeline, including the anticipated Type C FDA meeting and planned Phase 3 initiation, will also shape long-term expectations. Macroeconomic conditions, biotech financing sentiment, and any additional capital-raising activity are factors to monitor given the company's cash-burn profile. I’m watching this closely as these milestones unfold.
In my own research process, I regularly use Tickeron’s AI Trading Bots to test different strategies across various timeframes and market conditions. This helps me evaluate how automated approaches might respond to situations like the one facing ABEO, offering a data-driven perspective without replacing my own judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The RSI Oscillator for ABEO moved into overbought territory on November 19, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +13.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In 67 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for ABEO turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for ABEO moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ABEO entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.862) is normal, around the industry mean (3.596). P/E Ratio (-3.446) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (13.089) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. ABEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceutical products
Industry Biotechnology